Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven Grant

Showing results (101-110 of 386) with videos related to

Pageof 39
Sort By:
Leukemia Research|May 14, 2019
Corrigendum to "Adaphostin and bortezomib induce oxidative injury and apoptosis in imatinib mesylate-resistant hematopoietic cells expressing mutant forms of Bcr/Abl" [Leuk. Res. 30 (2006) 1263-1272]Girija Dasmahapatra, Tri K Nguyen, Paul Dent, et al.
Molecular Cancer Therapeutics|January 7, 2004
Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cellsRoberto R Rosato, Jorge A Almenara, Yun Dai, et al.
Molecular Pharmacology|July 6, 2004
Contribution of disruption of the nuclear factor-kappaB pathway to induction of apoptosis in human leukemia cells by histone deacetylase inhibitors and flavopiridolNing Gao, Yun Dai, Mohamed Rahmani, et al.
Blood|September 6, 2005
Synergistic antileukemic interactions between 2-medroxyestradiol (2-ME) and histone deacetylase inhibitors involve Akt down-regulation and oxidative stressNing Gao, Mohamed Rahmani, Xianglin Shi, et al.
Best Practice & Research. Clinical Obstetrics & Gynaecology|July 13, 2024
Antenatal screening for fetal structural anomalies - Routine or targeted practice?Rani Haj Yahya, Alina Roman, Steven Grant, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 4, 2012
PLK1 inhibitors synergistically potentiate HDAC inhibitor lethality in imatinib mesylate-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivoGirija Dasmahapatra, Hiral Patel, Tri Nguyen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 20, 2007
Synergistic interactions between vorinostat and sorafenib in chronic myelogenous leukemia cells involve Mcl-1 and p21CIP1 down-regulationGirija Dasmahapatra, Nitin Yerram, Yun Dai, et al.
Cancer Research|January 20, 2007
Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocationShuang Chen, Yun Dai, Hisashi Harada, et al.
Molecular Pharmacology|February 24, 2004
Evidence of a functional role for p21WAF1/CIP1 down-regulation in synergistic antileukemic interactions between the histone deacetylase inhibitor sodium butyrate and flavopiridolRoberto R Rosato, Jorge A Almenara, Chunrong Yu, et al.
Fetal Diagnosis and Therapy|February 5, 2005
The use of ultrasound measurement of fetal lung length to predict neonatal respiratory outcome after prolonged premature rupture of the membranesPeter Stone, Steven Grant, Lynn Sadler, et al.
Pageof 39

Showing results (101-110 of 386) with videos related to

Sort By:
Pageof 39
Leukemia Research|May 14, 2019
Corrigendum to "Adaphostin and bortezomib induce oxidative injury and apoptosis in imatinib mesylate-resistant hematopoietic cells expressing mutant forms of Bcr/Abl" [Leuk. Res. 30 (2006) 1263-1272]Girija Dasmahapatra, Tri K Nguyen, Paul Dent, et al.
Molecular Cancer Therapeutics|January 7, 2004
Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cellsRoberto R Rosato, Jorge A Almenara, Yun Dai, et al.
Molecular Pharmacology|July 6, 2004
Contribution of disruption of the nuclear factor-kappaB pathway to induction of apoptosis in human leukemia cells by histone deacetylase inhibitors and flavopiridolNing Gao, Yun Dai, Mohamed Rahmani, et al.
Blood|September 6, 2005
Synergistic antileukemic interactions between 2-medroxyestradiol (2-ME) and histone deacetylase inhibitors involve Akt down-regulation and oxidative stressNing Gao, Mohamed Rahmani, Xianglin Shi, et al.
Best Practice & Research. Clinical Obstetrics & Gynaecology|July 13, 2024
Antenatal screening for fetal structural anomalies - Routine or targeted practice?Rani Haj Yahya, Alina Roman, Steven Grant, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 4, 2012
PLK1 inhibitors synergistically potentiate HDAC inhibitor lethality in imatinib mesylate-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivoGirija Dasmahapatra, Hiral Patel, Tri Nguyen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 20, 2007
Synergistic interactions between vorinostat and sorafenib in chronic myelogenous leukemia cells involve Mcl-1 and p21CIP1 down-regulationGirija Dasmahapatra, Nitin Yerram, Yun Dai, et al.
Cancer Research|January 20, 2007
Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocationShuang Chen, Yun Dai, Hisashi Harada, et al.
Molecular Pharmacology|February 24, 2004
Evidence of a functional role for p21WAF1/CIP1 down-regulation in synergistic antileukemic interactions between the histone deacetylase inhibitor sodium butyrate and flavopiridolRoberto R Rosato, Jorge A Almenara, Chunrong Yu, et al.
Fetal Diagnosis and Therapy|February 5, 2005
The use of ultrasound measurement of fetal lung length to predict neonatal respiratory outcome after prolonged premature rupture of the membranesPeter Stone, Steven Grant, Lynn Sadler, et al.
Pageof 39